Leukemia Research

(The TQCC of Leukemia Research is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase68
Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia41
Acute leukemia in the time of COVID-1940
Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆31
A concise review on the molecular genetics of acute myeloid leukemia31
Covid-19 infection in therapy-naive patients with B-cell chronic lymphocytic leukemia29
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study27
Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia25
A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival20
Exosome-derived miR-let-7c promotes angiogenesis in multiple myeloma by polarizing M2 macrophages in the bone marrow microenvironment20
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis19
Cannabinoid CP55940 selectively induces apoptosis in Jurkat cells and in ex vivo T-cell acute lymphoblastic leukemia through H2O2 signaling mechanism19
Plasma cell leukemia: A review of the molecular classification, diagnosis, and evidenced-based treatment19
Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm18
Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells16
Plerixafor in combination with chemotherapy and/or hematopoietic cell transplantation to treat acute leukemia: A systematic review and metanalysis of preclinical and clinical studies16
Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia16
Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study16
Clonal hematopoiesis: Molecular and clinical implications16
Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement15
Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation15
Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia15
Long non-coding RNA CRNDE suppressing cell proliferation is regulated by DNA methylation in chronic lymphocytic leukemia14
The prognostic importance of BCR-ABL transcripts in Chronic Myeloid Leukemia: A systematic review and meta-analysis14
Hemorrhage in acute promyelocytic leukemia: Can it be predicted and prevented?14
Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy14
Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience13
Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemias12
miR-324-3p and miR-508-5p expression levels could serve as potential diagnostic and multidrug-resistant biomarkers in childhood acute lymphoblastic leukemia12
Disulfiram/cytarabine eradicates a subset of acute myeloid leukemia stem cells with high aldehyde dehydrogenase expression12
Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL)12
Tumor-associated macrophages modulate angiogenesis and tumor growth in a xenograft mouse model of multiple myeloma11
Procalcitonin and C-reactive protein predict infection in hematopoietic stem cell transplantation patients11
Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation in high-risk patients with myeloid malignancies is associated with a high rate of infectious11
A machine learning approach to predicting risk of myelodysplastic syndrome11
Patients with post polycythemia vera myelofibrosis might experience increased thrombotic risk in comparison to primary and post essential thrombocythemia myelofibrosis10
Iron overload regulate the cytokine of mesenchymal stromal cells through ROS/HIF-1α pathway in Myelodysplastic syndromes10
Long non-coding RNA LINC01003 suppresses the development of multiple myeloma by targeting miR-33a-5p/PIM1 axis10
Gilteritinib in the management of acute myeloid leukemia: Current evidence and future directions10
Acute myeloid leukemia with 11q23 rearrangements: A study of therapy-related disease and therapeutic outcomes9
Runt-related transcription factor 2 influences cell adhesion-mediated drug resistance and cell proliferation in B-cell non-Hodgkin’s lymphoma and multiple myeloma9
Vancomycin-resistant enterococci infection and predisposing factors for infection and mortality in patients with acute leukaemia and febrile neutropenia9
Sweet's syndrome associated with hematological malignancies9
Myelo-deception: Luspatercept & TGF-Beta ligand traps in myeloid diseases & anemia9
Association of insurance disparities and survival in adults with multiple myeloma: A non-concurrent cohort study9
Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes8
Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience8
NFYB potentiates STK33 activation to promote cisplatin resistance in diffuse large B-cell lymphoma8
High serum levels of IL-2R, IL-6, and TNF-α are associated with higher tumor burden and poorer outcome of follicular lymphoma patients in the rituximab era8
Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS8
Outcomes of haploidentical peripheral stem cell transplantation with combination of post-transplant cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) compared to unrelated donor transplantatio8
Treatment Failure in Acute Myeloid Leukemia: Focus on the Role of Extracellular Vesicles8
A fatal case of TEMPI syndrome, refractory to proteasome inhibitors and autologous stem cell transplantation8
A systematic review of primary gastric diffuse large B-cell lymphoma: Clinical diagnosis, staging, treatment and prognostic factors8
Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapy7
CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights7
A452, HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in IMiDs-resistant multiple myeloma7
The BALL prognostic score identifies relapsed/refractory CLL patients who benefit the most from single-agent ibrutinib therapy7
Prevalence and characteristics of myeloproliferative neoplasms with concomitant monoclonal gammopathy7
Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells7
Integration of the Ki-67 proliferation index into the Ogata score improves its diagnostic sensitivity for low-grade myelodysplastic syndromes7
MYC overexpression is associated with an early disease progression from MDS to AML7
MiR-665 suppresses the progression of diffuse large B cell lymphoma (DLBCL) through targeting LIM and SH3 protein 1 (LASP1)7
Metformin suppresses the growth of leukemia cells partly through downregulation of AXL receptor tyrosine kinase7
Outcome of allogeneic hematopoietic stem cell transplantation for T-cell lymphoblastic leukemia/lymphoma: A single-center study7
LncRNA landscape analysis identified LncRNA LEF-AS1 as an oncogene that upregulates LEF1 and promotes survival in chronic lymphocytic leukemia7
Aberrant expression profile of miR-32, miR-98 and miR-374 in chronic lymphocytic leukemia7
Untargeted metabolomics of newborn dried blood spots reveals sex-specific associations with pediatric acute myeloid leukemia7
IL-33/IL1RL1 axis regulates cell survival through the p38 MAPK pathway in acute myeloid leukemia7
Conversion to supportive care with biosimilar pegfilgrastim-cbqv enables budget-neutral expanded access to R-CHOP treatment in non-Hodgkin lymphoma7
Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update6
The pretreatment platelet count predicts survival outcomes of diffuse large B-cell lymphoma: An analysis of 1007 patients in the rituximab era6
Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax6
Diminished expression of 5hmc in Reed-Sternberg cells in classical Hodgkin lymphoma is a common epigenetic marker6
25-Hydroxy vitamin D deficiency predicts inferior prognosis in Hodgkin lymphoma6
Comparison of chidamide-contained treatment modalities versus chemotherapy in the second-line treatment for relapsed or refractory peripheral T-cell lymphoma6
Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG+/-Idarubicin versus 3 + 7 (Anthracycline + Cyt6
MiR-197-3p reduces bortezomib resistance in multiple myeloma by inhibiting IL-6 expression in a MEAF6-dependent manner6
Efficacy of 10-day decitabine in acute myeloid leukemia6
NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or MDS/MPN frequently harbours secondary-type mutations and confers inferior outcome compared to AML with mutated NPM16
Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs6
Measurable residual disease including AML leukemia stem cell flow evaluation of CPX-351 therapy by multi-parameter flow cytometry6
Treatment outcomes of patients with acute promyelocytic leukaemia between 2000 and 2017, a retrospective, single centre experience6
Clinical and molecular spectrum and prognostic outcomes of U2AF1 mutant clonal hematopoiesis- a prospective mayo clinic cohort study6
An antibody-drug conjugate with intracellular drug release properties showing specific cytotoxicity against CD7-positive cells6
SAMHD1 mutations in mantle cell lymphoma are recurrent and confer in vitro resistance to nucleoside analogues6
Psychometric evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF)6
Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia6
Philadelphia-positive B-lymphoblastic leukemia in a middle-income country – A real-world multicenter cohort6
Altered expression of NEAT1 variants and P53, PTEN, and BCL-2 genes in patients with acute myeloid leukemia6
Iron deficiency as promoter of heavy metals-induced acute myeloid leukemia6
Assessment of rituximab-abbs, a biosimilar, and rituximab outcomes in patients with CLL or NHL: A real-world UK study6
The incidence of non-Hodgkin lymphoma is increased in patients with obstructive sleep apnea6
Triazole antifungal use for prophylaxis and treatment of invasive fungal diseases for patients receiving gilteritinib6
Easier and more explanatory indices by integrating leukocyte lymphocyte ratio (LLR) and prognostic nutritional index (PNI) to IPS systems in cases with classical Hodgkin lymphoma6
Autoimmune disorders associated with myelodysplastic syndromes: clinical, prognostic and therapeutic implications5
MR 4log and low levels of NK cells are associated with higher molecular relapse after imatinib discontinuation: Results of a prospective trial5
Antihistamines are synergistic with Bruton’s tyrosine kinase inhibiter ibrutinib mediated by lysosome disruption in chronic lymphocytic leukemia (CLL) cells5
Novel pharmacological approach for the prevention of multidrug resistance (MDR) in a human leukemia cell line5
Dermatologic adverse events associated with IDH inhibitors ivosidenib and enasidenib for the treatment of acute myeloid leukemia5
The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement5
LncRNA CCAT2 expression at diagnosis predicts imatinib response in chronic phase chronic myeloid leukemia patients5
TH1 cytokines induce senescence in AML5
Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial5
The WHO 2016 diagnostic criteria for Acute Myeloid leukemia with myelodysplasia related changes (AML-MRC) produce a very heterogeneous entity: A retrospective analysis of the FAB subtype RAEB-T5
Incidence of myelodysplastic syndromes in Finland 1997–20165
Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) 5
No margin for non-adherence: Probabilistic kaplan-meier modeling of imatinib non-adherence and treatment response in CML (ADAGIO study)5
Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system5
Not all bad: Drug-induced interstitial pneumonia in DLBCL patients is potentially fatal but could be linked to better survival5
MYC protein expression does not correlate with MYC abnormalities detected by FISH but predicts an unfavorable prognosis in de novo acute myeloid leukemia5
Teenage mutant neutrophilic precursors: Leukemia cutis with IDH2 mutation on enasidenib therapy5
Pretreatment whole blood Epstein-Barr virus DNA predicts prognosis in Hodgkin lymphoma5
MYD88 L265P mutation detected by digital PCR as a prognostic factor in patients with diffuse large B-cell lymphoma in rituximab era5
Efficacy of ruxolitinib in acute lymphoblastic leukemia: A systematic review5
Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity5
Clonal compositions involving epigenetic regulator and splicing mutations in CHIP, CCUS, MDS, and CMML5
A phase I clinical trial to study the safety of treatment with tipifarnib combined with bortezomib in patients with advanced stages of myelodysplastic syndrome and oligoblastic acute myeloid leukemia5
Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: A systematic review of clinical trials5
High Bax/Bcl-2 ratio is associated with good prognosis and better survival in patients with B cell chronic lymphocytic leukemia5
Targeted therapy for treatment of patients with classical hairy cell leukemia5
Haploinsufficiency of multiple del(5q) genes induce B cell abnormalities in mice5
MicroRNA-211 attenuates cell proliferation in T-cell lymphoblastic lymphoma through targeting TCF125
From bone marrow failure syndromes to VEXAS: Disentangling clonal hematopoiesis, immune system, and molecular drivers5
Prognostic nutritional index, a novel biomarker which predicts worse prognosis in diffuse large B cell lymphoma5
Molecular genetic characterization of Philadelphia chromosome-positive acute myeloid leukemia5
Lineage switch to acute myeloid leukemia during induction chemotherapy for early T-cell precursor acute lymphoblastic leukemia with the translocation t(6;11)(q27;q23)/KMT2A-AFDN: A case report5
A single flow cytometric MRD measurement in children with B-lineage acute lymphocytic leukemia and hyperleukocytosis redefines the requirements of high-risk treatment: Results of the study ALL-MB 20085
LncRNA MEG3 promotes the sensitivity of bortezomib by inhibiting autophagy in multiple myeloma5
Evidence that knock down of GSK-3β in Chronic Myelogenous Leukemia cells augments IFN-γ-induced apoptosis5
Anagrelide in essential thrombocythemia: Efficacy and long-term consequences in young patient population4
Reinfection versus failure of viral clearance in a COVID-19 patient with hematologic malignancy4
Flow cytometric MRD at the end of consolidation in childhood B-lineage acute lymphoblastic leukemia has significant prognostic value but limited clinical implications: Results of study ALL-MB 20084
Terminal deoxynucleotidyl transferase (TdT) expression is associated with FLT3-ITD mutations in Acute Myeloid Leukemia4
Clinical characteristics and survival outcomes of newly diagnosed multiple myeloma patients presenting with extramedullary disease: A retrospective study4
A phase II study of sequential decitabine and rapamycin in acute myelogenous leukemia4
Plasmablastic lymphoma – single centre experience with infusional EPOCH chemotherapy4
CUDC-101 enhances the chemosensitivity of gemcitabine-treated lymphoma cells4
Central nervous system involvement in adult acute myeloid leukemia patients4
Subdiaphragmatic extranodal localizations at diagnosis of primary mediastinal large B-cell lymphoma: an impressive, rare presentation with no independent effect on prognosis4
Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarM4
Proposal and clinical application of molecular genetic risk scoring system, “MRplus”, for BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia- report from a single centre4
Ponatinib long-term follow-up of efficacy and safety in CP-CML patients in real world settings in France: The POST-PACE study4
RUNX1 mutations correlate with response to venetoclax combination therapies in relapsed/refractory acute myeloid leukemia4
Hybrid chemotherapy regimen (FLAG-IDA-vincristine-prednisone) for acute leukemia with mixed-phenotype blasts4
Radiation-Free myeloablative allogeneic hematopoietic stem cell transplantation for adult acute lymphoblastic leukemia: A comparison of outcomes between patients with and without central nervous syste4
Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease4
De Novo myelodysplastic syndromes in patients 20–50 years old are enriched for adverse risk features4
Eligibility for clinical trials is unsatisfactory for patients with myelodysplastic syndromes, even at a tertiary referral center4
Immunotherapy for Acute Myeloid Leukemia: Allogeneic hematopoietic cell transplantation is here to stay4
Impact of tyrosine kinase inhibitors on the statural growth in children with acute lymphoblastic leukemia4
Evidence that PKCα inhibition in Dalton’s Lymphoma cells augments cell cycle arrest and mitochondrial-dependent apoptosis4
Efficacy of blinatumomab for MRD relapse in ALL post allogenic HCT4
Glucose induced-AKT/mTOR activation accelerates glycolysis and promotes cell survival in acute myeloid leukemia4
A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML4
Spectrum of second primary malignancies and cause-specific mortality in pediatric and adult langerhans cell histiocytosis4
Impact of high dose cytarabine dosing strategies in obese patients with acute myeloid leukemia4
Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approval4
Chemotherapeutic drugs elicit stemness and metabolic alteration to mediate acquired drug-resistant phenotype in acute myeloid leukemia cell lines4
Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents4
Low serum cholesterol levels predict inferior prognosis and improve prognostic index scoring for peripheral T-cell lymphoma, unspecified4
Serum metabolomic profiling based on GC/MS helped to discriminate Diffuse Large B-cell Lymphoma patients with different prognosis4
Chronic eosinophilic leukemia with recurrent STAT5B N642H mutation—An entity with features of myelodysplastic syndrome/ myeloproliferative neoplasm overlap4
High mortality with High false negative rate: COVID-19 infection in patients with hematologic malignancies4
Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort4
Iron-mediated tissue damage in acquired ineffective erythropoiesis disease: It’s more a matter of burden or more of exposure to toxic iron form?4
Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting4
The impact of lockdown during the COVID-19 pandemic on newly acute myeloid leukemia patients: Single-centre comparative study between 2019 and 2020 cohorts in Madrid4
Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database4
Safety and outcomes of maintenance therapy with third-generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome positive acute lymphoblastic l4
Treatment of lymphomas via regulating the Signal transduction pathways by natural therapeutic approaches: A review4
Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia3
Midkine inhibitor (iMDK) induces apoptosis of primary effusion lymphoma via G2/M cell cycle arrest3
Development of Classic Hodgkin Lymphoma after successful treatment of primary mediastinal large b-cell lymphoma: results from a well-defined database3
Personalized at-home autologous hematopoietic stem cell transplantation during the SARS-CoV-2 outbreak3
Eltrombopag may induce bone marrow fibrosis in allogeneic hematopoietic stem cell transplant recipients with prolonged thrombocytopenia3
Additional flow cytometric studies for differential diagnosis between Burkitt lymphoma/leukemia and B-cell precursor acute lymphoblastic leukemia3
Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial3
Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients3
The effect of bulky mass on prognosis in diffuse large-B-cell lymphoma: still poor?3
Whole-genome optical mapping to elucidate myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions3
Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Ringing in a new future3
Strategy for identification of a potential inherited leukemia predisposition in a 299 patient’s cohort with tumor-only sequencing data3
Lymphocyte-depleting chemotherapy for aggressive hematologic malignancies in two patients with positive SARS-CoV-2 PCR3
Treatment of myeloid sarcoma without bone marrow involvement with gemtuzumab ozogamicin-containing regimen3
t(3;14)(p14.1;q32)/FOXP1-IGH translocation in thyroid extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)3
Effects of neuromuscular electrical stimulation combined with resistance exercises on muscle strength in adult hematological cancer patients: A randomized controlled study3
What’s germane in the germline? Finding clinically relevant germline variants in myeloid neoplasms from tumor only screening3
Risk adapted therapeutic strategy in newly diagnosed acute myeloid leukemia: Refining the outcomes of ELN 2017 intermediate-risk patients3
Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center3
Lenalidomide, bortezomib and dexamethasone followed by tandem- autologous stem cell transplantation is an effective treatment modality for multi-hit multiple myeloma3
Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system3
Factors affecting survival in elderly patients with diffuse large B-Cell lymphoma3
Concurrent myelodysplasia and monoclonal B lymphocytosis in VEXAS syndrome3
Mutational profiling of myeloid neoplasms associated genes may aid the diagnosis of acute myeloid leukemia with myelodysplasia-related changes3
Response assessment to venetoclax in relapsed/refractory chronic lymphocytic leukemia by ultrasonography3
Maternal obesity and acute lymphoblastic leukemia risk in offspring: A summary of trends, epidemiological evidence, and possible biological mechanisms3
Analysis of estimated clinical benefit of newly approved drugs for US patients with acute myeloid leukemia3
A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia3
Diagnostic and prognostic implications of tumor expression of the GATA-3 gene in nodal peripheral T-cell lymphoma (nPTCL): Retrospective data from a Latin American cohort3
Maintenance therapy with hypomethylating agents for patients with acute myeloid leukemia in first remission not eligible for allogeneic hematopoietic cell transplantation: A systematic review and meta3
CD5-positive marginal zone lymphoma: Clinicopathological features and survival outcomes3
Levocarnitine supplementation for asparaginase-induced hepatotoxicity in adult acute lymphoblastic leukemia patients: A multicenter observational study of the campus all group3
Anabolic steroids in myelodysplastic syndromes: A systematic review3
A national Danish proof of concept on feasibility and safety of home -based intensive chemotherapy in patients with acute myeloid leukemia3
CD94 expression patterns in reactive and neoplastic T-cell and NK-cell proliferations3
Clinical outcome of chronic myeloid leukemia patients who switch from first-line therapy with a second generation tyrosine kinase inhibitor to an alternative TKI3
Rare case of pediatric trilineal mixed-phenotype acute leukemia with t(11;19)(q23.3;p13)/KMT2A::ELL3
The outcome of Ph-negative acute lymphoblastic leukemia presenting during pregnancy and treated on the Russian prospective multicenter trial RALL-20093
Circ_SEC61A1 contributes to the progression of multiple myeloma cells via regulating miR-660-5p/CDK6 axis3
A higher percentage of leukemic blasts with vacuoles predicts unfavorable outcomes in patients with acute myeloid leukemia3
Autoimmune disorders and the risk of thrombotic events in polycythaemia vera3
Effect of single-unit transfusion in patients treated for haematological disease including acute leukemia: A multicenter randomized controlled clinical trial3
Differential characteristics of TP53 alterations in pure erythroid leukemia arising after exposure to cytotoxic therapy3
Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry3
Disturbed MAPK pathway in early bilateral testicular extramedullary relapse of multiple myeloma3
Discrepancy in transcriptomic profiling between CD34 + stem cells and primary bone marrow cells in myelodysplastic neoplasm2
PTPN11 mutations in adult acute myeloid leukaemia: Prevalence and clinical implications in the context of NPM1 mutation2
Frequency, variations, and prognostic implications of chromosome 14q32 deletions in chronic lymphocytic leukemia2
Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMA2
Evaluation of the Simplified Score to Predict Early Relapse in Multiple Myeloma (S-ERMM) in the MMRF CoMMpass study2
Deletions and amplifications of the IGH variable and constant regions:a novel prognostic parameter in patients with multiple myeloma2
Altered splicing and intronic polyadenylation of CSF3R via a cryptic exon in acute myeloid leukemia2
Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis2
The variable biological signature of refractory cytopenia of childhood (RCC), a retrospective EWOG-MDS study2
GATA1 downregulation in prefibrotic and fibrotic stages of primary myelofibrosis and in the myelofibrotic progression of other myeloproliferative neoplasms2
Imatinib responsive erythrocytosis in a patient with FIP1L1::PDGFRA rearranged myeloid neoplasm with hypereosinophilia – Another manifestation of a stem cell neoplasm2
Safety and efficacy of pracinostat in combination with gemtuzumab ozogamicin (PraGO) in patients with relapsed/refractory acute myeloid leukemia2
Prognostic impact of red cell distribution width in adult T-cell leukemia/lymphoma2
Acute leukemias with complex karyotype show a similarly poor outcome independent of mixed, myeloid or lymphoblastic immunophenotype: A study from the Bone Marrow Pathology Group2
Prognostic value of ASXL1 mutations in acute myeloid leukemia: A meta-analysis2
Late appearance of JAK2 mutated polycythaemia vera in a patient with typical chronic myeloid leukaemia on imatinib: Speculations about role of therapeutic pressure and of secondary genetic events2
Effect of cumulative daunorubicin dose on cardiotoxicity after allogeneic stem cell transplantation2
A systems genetics approach delineates the role of Bcl2 in leukemia pathogenesis2
MLL1 inhibition reduces IgM levels in Waldenström macroglobulinemia2
Hyperleukocytosis in patients with acute myeloid leukemia admitted to the intensive care unit: a single-center retrospective analysis2
Cutaneous leukocytoclastic vasculitis at diagnosis of hairy cell leukemia successfully treated with vemurafenib and rituximab2
Chronic myeloid leukemia, BCR-ABL1-positive, carrying NPM1 mutation – First case series from a single institution2
Pregnancy and long-term outcomes of female patients with chronic myeloid leukemia on tyrosine kinase inhibitors who experienced unplanned pregnancies2
Outcomes with molecularly targeted agents as salvage therapy following frontline venetoclax + hypomethylating agent in adults with acute myeloid leukemia: A multicenter retrospective analysis2
A strategy to reduce cumulative anthracycline exposure in low-risk pediatric acute myeloid leukemia while maintaining favorable outcomes2
Comparison of a modified pediatric protocol versus a hyper-CVAD protocol in adolescents and young adults with Philadelphia-negative acute lymphoblastic leukemia: A multicenter retrospective analysis2
Bortezomib-resistant multiple myeloma patient-derived xenograft is sensitive to anti-CD47 therapy2
The impact of anti-bacterial prophylaxis on the outcome of patients treated with venetoclax-based regimens for relapsed/refractory plasma cell dyscrasias: Real-life data2
ROR1 targeted immunoliposomal delivery of OSU-2S shows selective cytotoxicity in t(1;19)(q23;p13) translocated B-cell acute lymphoblastic leukemia2
Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: First results from a patient survey by the German Study Group for MPN2
The impact of tyrosine kinase inhibitors on allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia2
Management of humoral secondary immunodeficiency in hematological malignancies and following hematopoietic stem cell transplantation: Regional perspectives2
Diagnostic performance of F-18 FDG PET/CT in the detection of bone marrow involvement in paediatric hodgkin lymphoma: A meta-analysis2